ArticleFrontiers in microbiology2020
Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Eravacycline monotherapy and combination therapy against KPC-2- and NDM-1-co- producingFrontiers in microbiology · 2026Article
- Article
- Drug Resistance and Epidemiological Analysis of Carbapenem-Resistant Enterobacteriaceae in a Brain and Psychiatric Hospital of South China.Journal of clinical laboratory analysis · 2025Article
- Genomic and molecular characterization of a ceftazidime-avibactam resistant Klebsiella pneumoniae strain isolated from a Chinese tertiary hospital.BMC microbiology · 2025Article
- Molecular and epidemiological characterization of carbapenem-resistant hypervirulentFrontiers in cellular and infection microbiology · 2025Article
- Characterization of a KPC-84 harboring Klebsiella pneumoniae ST11 clinical isolate with ceftazidime-avibactam resistance.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Identification of a Novel KPC Variant, KPC-204, Conferring Resistance to Both Carbapenems and Ceftazidime-Avibactam in an ST11Microorganisms · 2024Article
- Molecular epidemiology of carbapenem-resistant gram-negative bacilli in Ecuador.BMC infectious diseases · 2024Article
- Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil.Revista da Sociedade Brasileira de Medicina Tropical · 2023Article
- A Seven-Year Microbiological and Molecular Study of Bacteremias Due to Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2022Article
- Increased Expression and Amplification ofMicrobiology spectrum · 2022Article
- Carbapenemase-Encoding Gene Copy Number Estimator (CCNE): a Tool for Carbapenemase Gene Copy Number Estimation.Microbiology spectrum · 2022Article
- Carbapenem antibiotic stress increases blaJournal of clinical laboratory analysis · 2022Article
- Multiple Novel Ceftazidime-Avibactam-Resistant Variants ofMicrobiology spectrum · 2022Article
- Emergence of Hypervirulent ST11-K64Frontiers in public health · 2022Article
- Molecular Mechanisms Mediating Ceftazidime/Avibactam Resistance Amongst Carbapenem-ResistantInfection and drug resistance · 2022Article
- Ceftazidime-avibactam: are we safe from class A carbapenemase producers' infections?Folia microbiologica · 2021Review
- Increased gene expression and copy number of mutated blaBMC microbiology · 2021Article
- Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-ProducingAntimicrobial agents and chemotherapy · 2021Article
- ISmBio · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.